Clinical Trials Browser

Unknown × Carcinoma, Hepatocellular × pembrolizumab × Clear all

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04224480 2024-01-19

Longitudinal Immune-phenotyping of HCC Following MK-3475

Phase 1 Unknown

8 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03099564 2023-02-06

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Phase EARLY_PHASE1 Unknown

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05339581 2022-04-27

iPLENTY-pvtt

Phase NA Unknown

78 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

176 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03337841 2017-11-09

Pembrolizumab as Neoadjuvant Treatment in HCC

Phase 2 Unknown

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Longitudinal Immune-phenotyping of HCC Following MK-3475

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

iPLENTY-pvtt

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Pembrolizumab as Neoadjuvant Treatment in HCC